Skip to main content

Vapotherm, Inc. (VAPO)

NYSE: VAPO · IEX Real-Time Price · USD
27.46 -1.02 (-3.58%)
Sep 20, 2021 10:59 AM EDT - Market open
Market Cap740.68M
Revenue (ttm)124.40M
Net Income (ttm)-57.30M
Shares Out25.89M
EPS (ttm)-2.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume37,312
Open28.20
Previous Close28.48
Day's Range27.26 - 28.73
52-Week Range16.64 - 38.46
Beta-1.59
AnalystsStrong Buy
Price Target41.50 (+51.1%)
Est. Earnings DateNov 3, 2021

About VAPO

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companio...

IndustryHealth Care Equipment & Supplies
IPO DateNov 14, 2018
CEOJoe Army
Employees397
Stock ExchangeNYSE
Ticker SymbolVAPO
Full Company Profile

Financial Performance

In 2020, Vapotherm's revenue was $125.73 million, an increase of 161.38% compared to the previous year's $48.10 million. Losses were -$51.50 million, 0.87% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Vapotherm stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 51.13% from the latest price.

Price Target
$41.50
(51.13% upside)
Analyst Consensus: Strong Buy

News

Vapotherm Raises Annual Sales Outlook Amid Surge In COVID-19 Cases

Vapotherm Inc (NYSE: VAPO) expects FY21 revenue of at least $102 million, an increase of $17 million over the low end of previous guidance of $85 million - $91 million. Related Content:   FDA Gives 510(...

1 week ago - Benzinga

Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables productio...

1 week ago - Business Wire

FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy

The FDA has granted 510(k) clearance to Vapotherm Inc's (NYSE:VAPO) HVT (high-velocity therapy) 2.0. Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool...

2 weeks ago - Benzinga

Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This n...

3 weeks ago - Business Wire

Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of -4.69% and 13.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Vapotherm Reports Second Quarter 2021 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

1 month ago - Business Wire

Analysts Estimate Vapotherm (VAPO) to Report a Decline in Earnings: What to Look Out for

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

1 month ago - Business Wire

Vapotherm to Report Second Quarter 2021 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...

1 month ago - Business Wire

Vapotherm to Host First Investor Day

EXETER, N.H,--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

3 months ago - Business Wire

Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

3 months ago - Business Wire

Vapotherm to Participate in the Bank of America Securities 2021 Health Care Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

4 months ago - Business Wire

Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of 2.44% and 2.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Vapotherm Reports First Quarter 2021 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

4 months ago - Business Wire

Will Vapotherm (VAPO) Report Negative Earnings Next Week? What You Should Know

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Vapotherm to Report First Quarter 2021 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...

4 months ago - Business Wire

Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of 10.53% and 0.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Vapotherm Reports Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

6 months ago - Business Wire

Vapotherm to Participate in Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic To...

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

7 months ago - Business Wire

Vapotherm to Report Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

7 months ago - Business Wire

Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

8 months ago - Business Wire

Vapotherm to Present at the 23rd Annual ICR/Westwicke Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

8 months ago - Business Wire

Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory The...

EXETER, N.H.--(BUSINESS WIRE)---- $VAPO--Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its propriet...

9 months ago - Business Wire

Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...

9 months ago - Business Wire

Vapotherm: The Game Has Completely Changed

Vapotherm's Hi-VNI technology is more comfortable and safer than current technologies used to treat patients with respiratory distress. The company has seen meaningful sales increases over the past two ...

10 months ago - Seeking Alpha